These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12538449)

  • 1. Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants.
    Wadler S; Yu B; Tan JY; Kaleya R; Rozenblit A; Makower D; Edelman M; Lane M; Hyjek E; Horwitz M
    Clin Cancer Res; 2003 Jan; 9(1):33-43. PubMed ID: 12538449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.
    Makower D; Rozenblit A; Kaufman H; Edelman M; Lane ME; Zwiebel J; Haynes H; Wadler S
    Clin Cancer Res; 2003 Feb; 9(2):693-702. PubMed ID: 12576437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma.
    Morley S; MacDonald G; Kirn D; Kaye S; Brown R; Soutar D
    Clin Cancer Res; 2004 Jul; 10(13):4357-62. PubMed ID: 15240522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.
    O'Shea CC; Johnson L; Bagus B; Choi S; Nicholas C; Shen A; Boyle L; Pandey K; Soria C; Kunich J; Shen Y; Habets G; Ginzinger D; McCormick F
    Cancer Cell; 2004 Dec; 6(6):611-23. PubMed ID: 15607965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
    Nemunaitis J; Ganly I; Khuri F; Arseneau J; Kuhn J; McCarty T; Landers S; Maples P; Romel L; Randlev B; Reid T; Kaye S; Kirn D
    Cancer Res; 2000 Nov; 60(22):6359-66. PubMed ID: 11103798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.
    Hann B; Balmain A
    J Virol; 2003 Nov; 77(21):11588-95. PubMed ID: 14557644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
    Mulvihill S; Warren R; Venook A; Adler A; Randlev B; Heise C; Kirn D
    Gene Ther; 2001 Feb; 8(4):308-15. PubMed ID: 11313805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
    Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
    Nemunaitis J; Cunningham C; Tong A; Post L; Netto G; Paulson AS; Rich D; Blackburn A; Sands B; Gibson B; Randlev B; Freeman S
    Cancer Gene Ther; 2003 May; 10(5):341-52. PubMed ID: 12719704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.
    Galanis E; Okuno SH; Nascimento AG; Lewis BD; Lee RA; Oliveira AM; Sloan JA; Atherton P; Edmonson JH; Erlichman C; Randlev B; Wang Q; Freeman S; Rubin J
    Gene Ther; 2005 Mar; 12(5):437-45. PubMed ID: 15647767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.
    Geoerger B; Grill J; Opolon P; Morizet J; Aubert G; Terrier-Lacombe MJ; Bressac De-Paillerets B; Barrois M; Feunteun J; Kirn DH; Vassal G
    Cancer Res; 2002 Feb; 62(3):764-72. PubMed ID: 11830531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein.
    Shen Y; Kitzes G; Nye JA; Fattaey A; Hermiston T
    J Virol; 2001 May; 75(9):4297-307. PubMed ID: 11287579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONYX-015. Onyx Pharmaceuticals.
    Cohen EE; Rudin CM
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1770-5. PubMed ID: 11892945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.
    Heise C; Lemmon M; Kirn D
    Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
    Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
    Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.
    Edwards SJ; Dix BR; Myers CJ; Dobson-Le D; Huschtscha L; Hibma M; Royds J; Braithwaite AW
    J Virol; 2002 Dec; 76(24):12483-90. PubMed ID: 12438574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.
    Rogulski KR; Freytag SO; Zhang K; Gilbert JD; Paielli DL; Kim JH; Heise CC; Kirn DH
    Cancer Res; 2000 Mar; 60(5):1193-6. PubMed ID: 10728673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells.
    Cherubini G; Petouchoff T; Grossi M; Piersanti S; Cundari E; Saggio I
    Cell Cycle; 2006 Oct; 5(19):2244-52. PubMed ID: 16969092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
    Vasey PA; Shulman LN; Campos S; Davis J; Gore M; Johnston S; Kirn DH; O'Neill V; Siddiqui N; Seiden MV; Kaye SB
    J Clin Oncol; 2002 Mar; 20(6):1562-9. PubMed ID: 11896105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells.
    Portella G; Pacelli R; Libertini S; Cella L; Vecchio G; Salvatore M; Fusco A
    J Clin Endocrinol Metab; 2003 Oct; 88(10):5027-32. PubMed ID: 14557490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.